Cell Therapy News

Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.

How Risky Is a Second Allogeneic Stem Cell Transplantation?

[Leukemia] In historic publications, a very high non-relapse mortality has been described, arguing against performing a second allogeneic stem cell transplantation (alloSCT). Investigators analyzed the outcome of 3356 second alloSCT performed 2011–21 following a hematologic malignancy relapse.

Stem Cell-Based Therapy for Fibrotic Diseases: Mechanisms and Pathways

[Stem Cell Research & Therapy] Scientists review the properties of various stem cell types utilized so far as anti-fibrotic treatments and discuss the challenges and limitations associated with their applications in clinical settings.

Precision Drug Delivery to the Central Nervous System Using Engineered Nanoparticles

[Nature Reviews Materials] The authors discuss how physiological barriers and disease-mediated changes in the blood–brain barrier and the overall brain can impact the precision delivery of therapeutics via the systemic route.

Successful Use of Anti-CD19 CAR T Cells in Severe Treatment-Refractory Stiff-Person Syndrome

[Proceedings of The National Academy of Sciences of The United States of America] CAR T cell infusion resulted in reduced leg stiffness, drastic improvement in gait, walking speed increase over 100%, and daily walking distance improvement from less than 50 m to over 6 km within 3 months.

Co-Stimulation of CD28/CD40 Signaling Molecule Potentiates CAR-T Cell Efficacy and Stemness

[Molecular Therapy] Scientists developed dual T/B cell co-stimulatory molecules in CAR-T cells to enhance intense tumoricidal activity and persistence. CD19.28.40z CAR-T cells promoted pNF-κB and pRelB downstream signaling while diminishing NFAT signaling upon antigen exposure.

Circular RNA-Based Therapy Provides Sustained and Robust Neuroprotection for Retinal Ganglion Cell

[Molecular Therapy] Researchers showed that circRNAs exhibiedt an exceptional capacity for prolonged protein expression and circRNA-expressed nerve growth factor protected cells from glucose deprivation.

MeCP2 Gene Therapy Ameliorates Disease Phenotype in Mouse Model for Pitt Hopkins Syndrome

[Neurotherapeutics] Researchers discovered that MeCP2 levels were decreased in PTHS patient iNPCs relative to healthy controls and that both iNPCs and iAstrocytes displayed defects in function and differentiation in a mutation-specific manner.

EBV Promotes TCR-T-Cell Therapy Resistance by Inducing CD163+M2 Macrophage Polarization and MMP9 Secretion

[Journal of Immunotherapy of Cancer] Flow cytometry was used for analyzing macrophage differentiation phenotypes induced by EBV-infected and EBV-uninfected tumors, as well as the function of T cells co-cultured with these macrophages.

Optimized RNA Interference Therapeutics Combined with Interleukin-2 mRNA for Treating Hepatitis B Virus Infection

[Signal Transduction and Targeted Therapy] Scientists developed a pan-genotypic and multifunctional small interfering RNA against hepatitis B virus with an efficient delivery system for treating chronic hepatitis B (CHB), and explore combined RNA interference and immune modulatory modalities for better viral control.

Proangiogenic Effect and Underlying Mechanism of Holmium Oxide Nanoparticles: A New Biomaterial for Tissue Engineering

[Journal of Nanobiotechnology] Investigators confirmed that holmium oxide nanoparticless promoted early vessel formation, especially that of H-type vessels in vivo, thereby accelerating bone tissue repair.

Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy

[Charles River Laboratories International, Inc.] Charles River Laboratories International, Inc. and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a plasmid DNA and retrovirus vector production program agreement.

Vertex Reports Positive Results in Stem Cell Trial for Type 1 Diabetes

[STAT News] welve people with type 1 diabetes who received a therapy derived from stem cells were able to produce enough of their own insulin to maintain healthy blood glucose levels 90 days later, Vertex Pharmaceuticals said Friday June 21st.

Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.

spot_img